New drug cocktail shows promise for tough lung cancer mutation
NCT ID NCT05751187
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of four drugs—pembrolizumab, bevacizumab, pemetrexed, and cisplatin—as a first treatment for people with advanced non-squamous lung cancer that has a specific EGFR exon 20 insertion mutation. The study enrolled 54 participants and measures how many patients' tumors shrink or disappear. The goal is to find a more effective option for this hard-to-treat cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab, bevacizumab, pemetrexed, and cisplatin
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with a hard-to-treat form of lung cancer.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The combination also carries risks like immune-related side effects and bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China